Developmental expression of NPY, PYY and PP in the rat pancreas and their coexistence with islet hormones.
It has been suggested that members of the neuropeptide Y (NPY) family of regulatory peptides [NPY, peptide YY (PYY) and pancreatic polypeptide (PP)] play an important role in the development of the endocrine pancreas. The development of rat endocrine pancreas from embryonic (E) day 12 until 30 days postpartum (P) was studied with emphasis on NPY, PYY and PP and their co-existence with insulin, glucagon and somatostatin using single and double immunostaining and in situ hybridization. Already at E12, PYY was detectable in small endocrine cell clusters and found to be co-localised with both insulin and glucagon, which at this stage occurred in the same cells. At E16 most of the insulin-immunoreactive (IR) cells were distinct from the glucagon/PYY-IR cells. Interestingly, at E16 NPY mRNA, and at E17 NPY immunoreactivity appeared in a few, scattered endocrine cells. Virtually all NPY-IR endocrine cells were insulin-producing beta cells. At E18 the endocrine cells started to form typical islets with centrally located insulin/NPY-IR cells surrounded by glucagon/PYY-IR cells. AT E20-E21, the vast majority of insulin-producing cells also expressed NPY. However, at birth (day 0) islet cell NPY mRNA was lacking. Postnatally the number and immunostaining intensity of NPY-IR islet cells rapidly declined, being non-detectable at P5. Cells containing PP immunoreactivity and PP mRNA were first detected at E21. The adult pattern of islet peptide distribution, with NPY confined to neuronal elements. PYY and PP exclusively in endocrine cells, was established at P5. The beta cell expression of NPY during the latter part of embryogenesis coincides with the prepartal glucocorticoid surge and with rapid islet cell replication and differentiation. This is compatible with steroid induction of NPY expression and with a role for NPY in the maturation of beta cells and their hormone release, which occurs in the immediate neonatal period.
Myrsén-Axcrona
U
U
Department of Physiology and Neuroscience, Lund University Hospital, University of Lund, Sweden.
Ekblad
E
E
Sundler
F
F
D000818:Animals; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005934:Glucagon / Q000032:analysis; D017403:In Situ Hybridization; D007328:Insulin / Q000032:analysis; D007515:Islets of Langerhans / Q000196:embryology* / Q000294:innervation / Q000378:metabolism; D008297:Male; D009478:Neuropeptide Y / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D010187:Pancreatic Hormones / Q000096:biosynthesis* / Q000235:genetics; D010191:Pancreatic Polypeptide / Q000096:biosynthesis* / Q000235:genetics; D010452:Peptide Biosynthesis; D019894:Peptide YY; D010455:Peptides / Q000235:genetics; D011498:Protein Precursors / Q000032:analysis; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013004:Somatostatin / Q000032:analysis
D007328:Insulin; D009478:Neuropeptide Y; D010187:Pancreatic Hormones; D010455:Peptides; D011498:Protein Precursors; D012333:RNA, Messenger; D019894:Peptide YY; C081158:proneuropeptide Y; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D005934:Glucagon